Gsa Capital Partners LLP Eagle Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$4.63 - $15.21 $267,109 - $877,480	57,691 Added 226.72%	83,137 $434,000
Q3 2023 Nov 15, 2023	SELL	$15.21 - $22.88 $169,378 - $254,791	-11,136 Reduced 30.44%	25,446 $401,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $396,630 - $712,549	22,358 Added 157.19%	36,582 $711,000
Q1 2023 May 12, 2023	BUY	$25.06 - $34.09 $356,453 - $484,896	14,224 New	14,224 $403,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $160,660 - $286,536	6,081 Added 35.65%	23,137 $611,000
Q2 2022 Aug 09, 2022	BUY	$41.26 - $51.35 $26,241 - $32,658	636 Added 3.87%	17,056 $758,000
Q1 2022 May 11, 2022	BUY	$44.58 - $52.6 $519,669 - $613,158	11,657 Added 244.74%	16,420 $813,000
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $218,240 - $271,014	4,763 New	4,763 $243,000
Q2 2020 Aug 11, 2020	SELL	$43.24 - $55.02 $265,580 - $337,932	-6,142 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$34.37 - $60.07 $145,213 - $253,795	-4,225 Reduced 40.75%	6,142 $283,000
Q4 2019 Feb 12, 2020	SELL	$54.32 - $64.31 $80,122 - $94,857	-1,475 Reduced 12.46%	10,367 $623,000
Q3 2019 Nov 12, 2019	SELL	$53.25 - $59.98 $381,483 - $429,696	-7,164 Reduced 37.69%	11,842 $670,000
Q2 2019 Aug 06, 2019	SELL	$46.61 - $58.45 $188,584 - $236,488	-4,046 Reduced 17.55%	19,006 $1.06 Million
Q1 2019 May 15, 2019	SELL	$38.66 - $51.82 $361,393 - $484,413	-9,348 Reduced 28.85%	23,052 $1.16 Million
Q4 2018 Feb 12, 2019	BUY	$36.72 - $67.73 $312,120 - $575,705	8,500 Added 35.56%	32,400 $1.31 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $1.24 Million - $1.56 Million	18,600 Added 350.94%	23,900 $1.66 Million
Q2 2018 Aug 09, 2018	SELL	$51.25 - $76.62 $128,125 - $191,550	-2,500 Reduced 32.05%	5,300 $401,000
Q1 2018 May 11, 2018	SELL	$52.16 - $66.86 $1.67 Million - $2.14 Million	-32,000 Reduced 80.4%	7,800 $411,000
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $1.19 Million - $1.45 Million	23,900 Added 150.31%	39,800 $2.13 Million
Q3 2017 Nov 20, 2017	BUY	$46.62 - $60.36 $741,258 - $959,724	15,900	15,900 $948,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account